Aesculus Bio ApS: Financial statements 2023
CVR: 40560866
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Aesculus Bio ApS (CVR 40560866) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -13,631 and a net result of DKK -10,881 compared with DKK -14,524 the year before. Equity in the 2023 report amounted to DKK 141,205. The solvency ratio was 52.4%.
- Gross Profit
- DKK -13,631
- Profit/Loss
- DKK -10,881
- Equity
- DKK 141,205
- Total Assets
- DKK 269,714
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -14 t. | -11 t. | 141 t. | - |
| 2022 | - | -25 t. | -15 t. | 152 t. | - |
| 2021 | - | 88 t. | 74 t. | 167 t. | - |
| 2020 | - | -12 t. | -15 t. | 93 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Aesculus Bio ApS has published its annual report for 2022. Gross profit came to DKK -25,019, and the net result was DKK -14,524.
About Aesculus Bio ApS
Aesculus Bio ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Benjamin Anderschou Holbech Jensen. The board consists of Peter Hviid Nordkild (chair) and Benjamin Anderschou Holbech Jensen. The company is owned by Benjamin Anderschou Holbech Jensen, PN INVESTMENT ApS and Jan Wehkamp. In 2025, the company reported a gross profit of DKK -154,862 and a net result of DKK -129,437 compared with DKK -45,866 the year before. Equity in the 2025 report amounted to DKK -34,097.